Biosimilars and biobetters present a lucrative ... have to follow the principles and guidelines as applicable for new molecules. However, there is a potential to refer to publically available ...

The IQVIA Institute for Human Data Science Study has developed a specific forecast for these new biosimilar molecules in oncology. The majority of the savings will be from three top-selling ...

Sarfaraz K. Niazi, PhD, gives his opinion on how the recent IQVIA report “Assessing the Biosimilar Void in the US” could be ...

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

1. The Department of Health has confirmed that a remit referred to NICE enables NICE to decide to apply the same remit, and resulting guidance, to relevant licensed biosimilar products which ...

As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...

However, biosimilars are complex, large molecules that are challenging to characterize. To win approval, companies must present comprehensive data showing that the biosimilar is comparable to the ...

Innovation isn’t just about new molecules and antibodies; it’s also about finding new ways to deliver existing treatments. Our biosimilars program, for example, is forging new ground in making ...

However, the rebate game played by drug manufacturers and pharmacy benefit managers in the U.S. limits optimal biosimilar competition. As a result, U.S. patient out-of-pocket costs are too high.

In accordance with the biosimilar guidelines of NMPA ... a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination ...